Postmarketing safety of migraine prophylactic monoclonal antibodies: An <scp>EudraVigilance</scp> database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab
Almost all of the most reported and statistically significant adverse events were nonserious and consistent with the existing literature. Given the chronic nature of migraine treatment, continuous pharmacovigilance monitoring is essential to ensure their constant safe use in clinical practice.
Authors
- Nicola Montanaro (ORCID: https://orcid.org/0000-0002-5710-8077)
- Victoria Nikitina (ORCID: https://orcid.org/0000-0002-0089-3043)
- Greta Santi Laurini (ORCID: https://orcid.org/0000-0002-7897-2956)
- Domenico Motola (ORCID: https://orcid.org/0000-0001-6253-4014)
Institutions
- University of Bologna (IT)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1111/head.14962
- Citations
- 7
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 9.15